NGS Scientist, New Technology Development

Organization
NanoString Technologies
Job Location
530 Fairview Ave N
Seattle, WA 98119
Salary
DOE
Benefits

Benefits include but are not limited to: Medical, Dental, Vision, Stock Options, ESPP, Matching 401K, transportation assistance, wellness reimbursement, PTO, and more..

Job Description

Job Summary:

NanoString Technologies is seeking a highly motivated and technology-savvy molecular biologist/biochemist, who will join R&D's New Technology Development group.  This position will have a central role on the development of sequencing chemistry of the recently announced Hyb & SeqTM technology, a novel single-molecule hybridization-based next generation sequencing.  He or she will act as, at times, lead scientist and project leader and will interact/coordinate with a highly interdisciplinary group of technologists to achieve complex technical goals.  Successful candidate must have strong analytical and quantitative skills, strong oral and written communication skills, a strong track record of independent as well as collaborative research, and proven technical leadership experience.

Essential Functions:

  • Apply advanced and expert scientific knowledge to sequencing chemistry development project
  • Take initiatives to conceive, design and carry-out hypothesis driven feasibility experiments, understanding both theoretical and practical aspects of the experimental design
  • Drive wet-bench experimentation and subsequent data analysis/interpretation activities
  • Work interactively with biophysicists, nucleic-acid chemists, fluorescence imaging specialists, and hardware/software engineers
Requirements
  • Ph.D. in Life/Chemical/Physical Sciences
  • 4+ years of industrial and/or post-doctoral work experience in next generation sequencing (NGS)
  • Extensive hands-on, state-of-the-art molecular biology experience
  • Track-record of working with novel synthetic chemistry and/or surface chemistry to improve nucleic acid manipulations
  • Broad knowledge of nucleic acid characterization techniques, especially hybridization-based assays
  • Experience with fluorescence-based detection technologies
  • Able to develop biological/chemical reagents and methods as needed
  • Able to identify and evaluate commercial technologies to determine their appropriateness and usefulness in technology innovation/development

Additional Qualifications include:

  • Experience with NGS bioinformatics
  • Advanced skills in statistical analysis
About Our Organization

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable.

Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.

 

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.

Gladys Kong writes at Fortune that her STEM background has helped her as a CEO.

Social scientists report that the image of the 'lone scientist' might be deterring US students from STEM careers.